Rene van der Linden, Pharm.D               Chief Executive Officer

Mr Van der Linden obtained a MSc in pharmacy and his Pharm.D at the University of Utrecht, the Netherlands. Further he holds a bachelor’s degree in Business Economics. He has 20 years of experience in bringing projects forward due to several commercial, strategic and executional positions at SmithKline Beecham, Organon France, Organon Head quarters, Pantarhei Bioscience. Rene is the founder of MEDIR.

Prof. Frans Merkus, Pharm.D, Ph.D        Chief Scientific Advisor

Mr. Merkus, emeritus professor Bio-pharmaceutics at the Dutch Universities of Amsterdam and of Leiden, is a key opinion leader in intranasal drug delivery. He is the (co-) author of more than 200 international scientific publications and several reference books and he was supervisor of more than a dozen Ph D students. Beside his scientific career, he has extensive experience in running and guiding businesses.

Ronald van der Geest. Ph.D                    Chief Development Officer

Mr Van der Geest holds a MSc from Leiden University, the Netherlands and UC San Francisco and a Ph.D from the Leiden/Amsterdam Centre for Drug Research. Ronald has a broad experience in clinical and preclinical development, due to positions at Johnson & Johnson, TiboTec and Kinesis Pharma. Ronald is co-founder of 3D-PharmXchange.

Lars Bastiaanse, Ph.D                              Regulatory

Mr. Bastiaanse studied pharmacy at the University of Utrecht, the Netherlands and obtained his PhD at the department of Cardiology of the Leiden University Medical Centre, the Netherlands. He gained vast experience in the area of regulatory affairs, clinical development and drug development, with Pharmachemie (Teva), Johnson & Johnson, TiboTec, PMD Consulting and Kinesis Pharma. Lars founded 3D-PharmXchange in 2010.

Bert Haenen, Ph.D                                     Non-clinical

Mr Haenen holds a MSc in biology from Radboud University in Nijmegen, the Netherlands and a Ph.D in toxicology from Wageningen University in the Netherlands. Bert has many years of experience in non-clinical drug development in positions at the Dutch Medicines Evaluation Board, the European Medicines Agency and at Merck, Schering-Plough and Organon. He is currently employed by 3D-PharmXchange.

Lieven Baert, Ph.D, MBA                          CMC

Mr Baert studied at the University of Ghent, Belgium where he obtained the degrees of Pharmacist, Industrial Pharmacist, Ph.D in Pharmaceutical Technology and a MBA. Lieven’s expertise is within CM&C. He worked for Merck Canada, Jansen Pharmaceutica, and others. Lieven founded Jalima Pharma and operates also through 3D-PharmXchange.

Further the team is assisted by external experts, i.e. anaesthesiologists, neurologists, a clinical pharmacologist and a regulatory expert.